Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACETNASDAQ:ALLRNASDAQ:NVCTNASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.74-2.6%$0.88$0.74▼$2.40$60.77M1.97817,563 shs346,907 shsALLRAllarity Therapeutics$0.91-2.9%$1.03$0.68▼$174.00$4.04M0.26972,654 shs991,893 shsNVCTNuvectis Pharma$9.35-4.3%$7.53$4.44▼$11.80$218.72M0.23118,849 shs88,075 shsPYRGFPyroGenesis Canada$0.37+4.3%$0.40$0.29▼$0.80$68.55M0.7413,332 shs11,630 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio-2.65%-16.95%-18.22%-23.60%-69.38%ALLRAllarity Therapeutics-3.18%-18.01%+13.95%-22.21%-99.43%NVCTNuvectis Pharma-4.30%+7.72%+39.76%+72.83%+17.91%PYRGFPyroGenesis Canada+4.32%-5.29%-12.57%-5.85%+14.75%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio3.4024 of 5 stars3.35.00.00.03.42.50.6ALLRAllarity Therapeutics0.7516 of 5 stars0.04.00.00.02.50.00.6NVCTNuvectis Pharma2.3058 of 5 stars3.50.00.00.01.25.00.6PYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$7.50920.41% UpsideALLRAllarity Therapeutics 0.00N/AN/AN/ANVCTNuvectis Pharma 3.00Buy$15.0060.43% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALLR, PYRGF, ACET, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025ACETAdicet BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/7/2025ACETAdicet BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/27/2025ACETAdicet BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/25/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $11.002/6/2025ACETAdicet BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform2/5/2025ACETAdicet BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M2.43N/AN/A$2.43 per share0.30ALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/APYRGFPyroGenesis Canada$9.14M7.50N/AN/A($0.01) per share-36.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$142.66M-$1.34N/AN/AN/AN/A-53.85%-46.45%5/13/2025 (Estimated)ALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%4/4/2025 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.11N/AN/AN/AN/A-155.80%-104.02%5/6/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.06N/A∞N/A-115.14%N/A-60.81%N/ALatest ALLR, PYRGF, ACET, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2025Q4 2024ACETAdicet Bio-$0.37-$0.32+$0.05-$0.32N/AN/A3/4/2025Q4 2024NVCTNuvectis Pharma-$0.28-$0.36-$0.08-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet Bio$0.045.44%N/AN/A N/AALLRAllarity TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A10.6410.64ALLRAllarity TherapeuticsN/A2.752.75NVCTNuvectis PharmaN/A2.742.74PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%ALLRAllarity Therapeutics11.53%NVCTNuvectis Pharma96.77%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio19.10%ALLRAllarity Therapeutics0.08%NVCTNuvectis Pharma35.78%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9082.69 million66.66 millionOptionableALLRAllarity Therapeutics104.43 million4.43 millionNot OptionableNVCTNuvectis Pharma823.39 million12.41 millionNot OptionablePYRGFPyroGenesis Canada90186.69 million96.34 millionNo DataALLR, PYRGF, ACET, and NVCT HeadlinesRecent News About These CompaniesPyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call TranscriptApril 1 at 1:02 PM | seekingalpha.comPyroGenesis Announces Fourth Quarter and Full Year 2024 ResultsMarch 31 at 11:02 PM | globenewswire.comPyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference CallMarch 26, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Shares Down 4.2% - Here's What HappenedMarch 26, 2025 | americanbankingnews.comPyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 4.2% - Here's WhyMarch 26, 2025 | marketbeat.comPyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | finanznachrichten.dePyroGenesis Provides Update on Varennes Carbon Recycling ProjectMarch 21, 2025 | globenewswire.comHPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica ProductionMarch 12, 2025 | markets.businessinsider.comPyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)March 11, 2025 | globenewswire.comPyroGenesis Provides Response to Impact of U.S. TariffsMarch 4, 2025 | globenewswire.comPyroGenesis in final stages of Boeing supplier qualification for course titanium powderMarch 4, 2025 | pm-review.comPyroGenesis Improves Key Performance Parameters of its NexGenTM Plasma Atomized Metal Powder Production SystemMarch 4, 2025 | markets.businessinsider.comPyroGenesis Canada (NASDAQ:PYRGF) Shares Up 2.9% - Here's What HappenedMarch 4, 2025 | marketbeat.comTechnical Requirements for Titanium Coarse Metal Powder Have Been Met by PyroGenesis' NexGen™ Plasma Atomized Metal Powder for Global Aerospace OEMMarch 3, 2025 | globenewswire.comPyroGenesis Announces First Material Produced from Fumed Silica ReactorFebruary 27, 2025 | globenewswire.comPyroGenesis signs plasma torch contract with Norsk HydroFebruary 24, 2025 | msn.comPyroGenesis Signs $2.4 Million Contract with Norsk Hydro ASAFebruary 24, 2025 | markets.businessinsider.comPyroGenesis signs second biogas contract with global leaderFebruary 18, 2025 | msn.comPFAS Destruction Testing Confirms That PyroGenesis’ Plasma Torches Reduce Energy Requirements By Up To 45%February 10, 2025 | markets.businessinsider.comPFAS Destruction Testing Confirms That PyroGenesis' Plasma Torches Reduce Energy Requirements By Up To 45%February 10, 2025 | globenewswire.comPyroGenesis Provides Update on Impact of Potential U.S. TariffsFebruary 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, PYRGF, ACET, and NVCT Company DescriptionsAdicet Bio NASDAQ:ACET$0.74 -0.02 (-2.65%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$0.74 +0.00 (+0.41%) As of 04/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Allarity Therapeutics NASDAQ:ALLR$0.91 -0.03 (-2.86%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$0.88 -0.03 (-2.76%) As of 04/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Nuvectis Pharma NASDAQ:NVCT$9.35 -0.42 (-4.30%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$9.30 -0.04 (-0.48%) As of 04/1/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.PyroGenesis Canada NASDAQ:PYRGF$0.37 +0.02 (+4.32%) As of 04/1/2025 10:35 AM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
